$10.31
0.29% day before yesterday
Nasdaq, Oct 03, 10:10 pm CET
ISIN
US82835W1080
Symbol
SPRY

Silverback Therapeutics Stock price

$10.31
-0.57 5.24% 1M
-3.09 23.06% 6M
-0.24 2.27% YTD
-3.69 26.36% 1Y
+4.88 89.87% 3Y
-10.69 50.90% 5Y
-10.69 50.90% 10Y
-10.69 50.90% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.03 0.29%
ISIN
US82835W1080
Symbol
SPRY
Industry

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$778.8m
Net debt
positive
Cash
$240.1m
Shares outstanding
98.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.1 | 12.2
EV/Sales
6.9 | 9.3
EV/FCF
negative
P/B
5.3
Financial Health
Equity Ratio
73.1%
Return on Equity
3.1%
ROCE
-22.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$112.3m | $83.4m
EBITDA
$-58.7m | $-150.2m
EBIT
$-59.3m | $-176.1m
Net Income
$-48.0m | $-165.4m
Free Cash Flow
$-53.4m
Growth (TTM | estimate)
Revenue
22,368.0% | -6.4%
EBITDA
-3.6% | -4,941.5%
EBIT
-4.6% | -5,617.2%
Net Income
-7.1% | -2,168.0%
Free Cash Flow
-20.7%
Margin (TTM | estimate)
Gross
93.7%
EBITDA
-52.3% | -180.1%
EBIT
-52.8%
Net
-42.7% | -198.3%
Free Cash Flow
-47.5%
More
EPS
$-0.5
FCF per Share
$-0.5
Short interest
35.6%
Employees
165
Rev per Employee
$540.0k
Show more

Is Silverback Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Silverback Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Silverback Therapeutics forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Silverback Therapeutics forecast:

Buy
92%
Hold
8%

Financial data from Silverback Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
112 112
22,368% 22,368%
100%
- Direct Costs 7.06 7.06
-
6%
105 105
-
94%
- Selling and Administrative Expenses 150 150
288% 288%
134%
- Research and Development Expense 14 14
22% 22%
13%
-59 -59
4% 4%
-52%
- Depreciation and Amortization 0.61 0.61
917% 917%
1%
EBIT (Operating Income) EBIT -59 -59
5% 5%
-53%
Net Profit -48 -48
7% 7%
-43%

In millions USD.

Don't miss a Thing! We will send you all news about Silverback Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Silverback Therapeutics Stock News

Neutral
GlobeNewsWire
6 days ago
Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced it has entered into a senior s...
Positive
Seeking Alpha
13 days ago
ARS Pharmaceuticals offers significant upside driven by neffy, the only FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. ARS faces near-term pressure from a patent challenge by Lupin, but even pessimistic scenarios suggest the stock is at least fairly valued. Base case fair value is $24.29 (138% upside), while the pessimistic scenario yields $12.25 (20% upside) fr...
Neutral
GlobeNewsWire
18 days ago
– Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced the appointment of Laura Shawver, Ph.D.
More Silverback Therapeutics News

Company Profile

Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson on January 4, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Richard Lowenthal
Employees 165
Founded 2015
Website ars-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today